|
Real-time Estimate
Cboe BZX
12:45:56 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 20.71 USD | -1.43% |
|
-7.77% | -33.35% |
| 08-14 | Oppenheimer Adjusts Pelthos Therapeutics PT to $64 From $66, Maintains Outperform Rating | MT |
| 08-13 | Pelthos Therapeutics Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
Company Valuation: Pelthos Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 3.864 | 95.69 | 80.44 | - | - |
| Change | - | 2,376.4% | -15.94% | - | - |
| Enterprise Value (EV) | 3.864 | 95.69 | 80.44 | 80.44 | 80.44 |
| Change | - | 2,376.4% | -15.94% | 0% | 0% |
| P/E | -0.45x | -1.35x | -1.23x | -7.47x | 9.13x |
| PBR | - | - | - | - | - |
| PEG | 0x | -0x | 0x | 0.1x | -0x |
| Capitalization / Revenue | - | 5.7x | 1.26x | 0.72x | 0.51x |
| EV / Revenue | - | 0x | 1.26x | 0.72x | 0.51x |
| EV / EBITDA | - | -0x | -2.53x | 12x | 3.41x |
| EV / EBIT | - | -0x | -1.68x | -9.21x | 3.58x |
| EV / FCF | - | - | -7.31x | 80.4x | 1.79x |
| FCF Yield | - | - | -13.7% | 1.24% | 55.9% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -14.3 | -23.04 | -17.12 | -2.813 | 2.302 |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | - | 16.8 | 63.75 | 112.2 | 159.2 |
| EBITDA 1 | - | -24.68 | -31.75 | 6.7 | 23.6 |
| EBIT 1 | - | -32.43 | -47.97 | -8.737 | 22.46 |
| Net income 1 | -7.955 | -43.32 | -62.08 | -24.96 | 10.79 |
| Net Debt | - | - | - | - | - |
| Reference price 2 | 6.41 | 31.00 | 21.01 | 21.01 | 21.01 |
| Nbr of stocks (in thousands) | 603 | 3,087 | 3,828 | - | - |
| Announcement Date | 3/27/25 | 3/19/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.23x | - | - | - | 80.44M | |
| 32.9x | 11.93x | 24.23x | 0.6% | 1,031B | |
| 29.45x | 6.54x | 18.31x | 2.02% | 638B | |
| 33.1x | 7.75x | 16.02x | 2.65% | 462B | |
| 105.72x | 5.91x | 25.05x | 2.35% | 359B | |
| 19x | 4.63x | 11.48x | 2.87% | 335B | |
| 20.37x | 5.28x | 13.08x | 3.03% | 273B | |
| 20.79x | 4.31x | 12.28x | 2.05% | 253B | |
| 26.62x | 6.92x | 12.32x | 2.39% | 228B | |
| -45.08x | 6.57x | 25.65x | 2.21% | 185B | |
| Average | 24.16x | 6.65x | 17.60x | 2.24% | 376.39B | |
| Weighted average by Cap. | 32.10x | 7.72x | 18.90x | 1.92% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PTHS Stock
- Valuation Pelthos Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
